ELL Antibody [B15J21]

Catalog No.: F9375

Application: Reactivity: Human, Mouse, Rat

Lane 1: 293T, Lane 2: 3T3, Lane 3: C2C12, Lane 4: H-4-II-E

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:100 IF1:1600 CHIP1:100

Application
WB, IP, IF, ChIP

Source
Rabbit Monoclonal Antibody

Reactivity
Human, Mouse, Rat

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
70 kDa

Datasheet & SDS

生物学的記述

Specificity
ELL Antibody [B15J21] detects endogenous levels of total ELL protein.

Clone
B15J21

Synonym(s)
RNA polymerase II elongation factor ELL; ELL

Background
Eleven‑nineteen lysine‑rich leukemia protein (ELL) is an RNA polymerase II (Pol II) elongation factor that regulates transcriptional elongation kinetics and contributes to both general Pol II activity and gene‑specific activation programs. ELL interacts directly with the Pol II machinery and contains conserved domains that contact the elongating polymerase and link it to larger regulatory complexes such as the super elongation complex (SEC), where it associates with AFF family members, AF4/AF9/ENL, P‑TEFb, EAF1/2, and other SEC subunits to orchestrate the transition from promoter‑proximal pausing to productive elongation. ELL enhances the catalytic rate of Pol II by suppressing transient pausing and stabilizing early elongation complexes, and it participates in the establishment and clearance of pause sites genome‑wide, ensuring rapid and high‑amplitude transcriptional responses for inducible and developmentally regulated genes. ELL is incorporated into the SEC alongside MLL‑fusion partners, and chromosomal translocations that juxtapose the MLL gene with ELL generate oncogenic MLL–ELL fusions that recruit the SEC to MLL‑regulated loci such as HOX gene clusters, driving aberrant HOX expression and disrupting normal differentiation programs that underlie acute myeloid and lymphoid leukemias.

Background

Eleven‑nineteen lysine‑rich leukemia protein (ELL) is an RNA polymerase II (Pol II) elongation factor that regulates transcriptional elongation kinetics and contributes to both general Pol II activity and gene‑specific activation programs. ELL interacts directly with the Pol II machinery and contains conserved domains that contact the elongating polymerase and link it to larger regulatory complexes such as the super elongation complex (SEC), where it associates with AFF family members, AF4/AF9/ENL, P‑TEFb, EAF1/2, and other SEC subunits to orchestrate the transition from promoter‑proximal pausing to productive elongation. ELL enhances the catalytic rate of Pol II by suppressing transient pausing and stabilizing early elongation complexes, and it participates in the establishment and clearance of pause sites genome‑wide, ensuring rapid and high‑amplitude transcriptional responses for inducible and developmentally regulated genes. ELL is incorporated into the SEC alongside MLL‑fusion partners, and chromosomal translocations that juxtapose the MLL gene with ELL generate oncogenic MLL–ELL fusions that recruit the SEC to MLL‑regulated loci such as HOX gene clusters, driving aberrant HOX expression and disrupting normal differentiation programs that underlie acute myeloid and lymphoid leukemias.

References
[1] Byun JS, et al. Nat Commun. 2012 Jan 17;3:633. [2] Shilatifard A, et al. J Biol Chem. 1997 Aug 29;272(35):22355-63.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%